Impact of-455G/A polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We aimed to investigate the association of aspirin and/or clopidogrel low response with-455G/A polymorphism of β-fibrinogen in patients with acute coronary syndrome (ACS). We enrolled 114 consecutive patients (mean age 61 ± 7, 31 female [27.2%], 83 male [72.8%]) with a first ACS. The diagnostic criteria for ACS were based on current guidelines. The-455 G/A β-fibrinogen polymorphism genotype distribution in the patient group was determined as the following: 54.4% GG homozygote, 39.5% GA, and 6.1% AA homozygote. Clopidogrel low response was present in 25 (21.9%) patients, aspirin low response in 21 (18.4%) patients, and dual antiplatelet low response in 9 (7.9%) patients. In our study, no difference was observed in terms of the distribution of-455 G/A β-fibrinogen polymorphism between the groups with and without aspirin and/or clopidogrel or dual antiplatelet low response in the patient group who underwent aspirin and clopidogrel treatment for ACS (P >.05). © 2013 The Author(s).

Cite

CITATION STYLE

APA

Sevimli, S., Karakoyun, S., Bakirci, E. M., Topcu, S., Kalkan, K., Borekci, A., & Vançelik, S. (2014). Impact of-455G/A polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome. Clinical and Applied Thrombosis/Hemostasis, 20(3), 238–243. https://doi.org/10.1177/1076029613508601

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free